
Psyence Group
A biotech company specializing in palliative care, with a focus on anxiety and depression, operating a federally licensed psilocybin cultivation facility, and developing non-synthetic psilocybin-based psychedelic medicines, listed on Nasdaq and CSE.
Market cap
$1.9m
Enterprise value
($5m)
Share price
CAD0.17 PSYG.CN
Authorizing premium user...